# OnCo record colorectal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/colorectal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "colorectal" ;
  schema:name "Colorectal cancer"@en ;
  schema:alternateName "COAD"@en, "COADREAD"@en, "TCGA-COAD"@en, "TCGA-COADREAD"@en, "colorectal adenocarcinoma (TCGA COAD and READ cohorts)"@en, "Rectal Cancer"@en ;
  schema:description "The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/colorectal/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Colorectal_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q188874> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461>, <https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-gastrointestinal-cancers/>, <https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq> ;
  onco:tag "gi", "spike" ;
  onco:related <https://onco.cc/collections/colorectal-cancer-alliance/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/mced/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/probiotics-treatment-diarrhoea/>, <https://onco.cc/technologies/hydrazine-sulfate/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/exercise-oncology/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/tempus-xt-cdx/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/oncodetect/>, <https://onco.cc/drugs/ziv-aflibercept/>, <https://onco.cc/drugs/catumaxomab/>, <https://onco.cc/drugs/tegafur-gimeracil-oteracil/> ;
  onco:companies <https://onco.cc/companies/ambagon-therapeutics/>, <https://onco.cc/companies/mabwell-shanghai-bioscience/>, <https://onco.cc/companies/multitude-therapeutics/>, <https://onco.cc/companies/neonc-technologies/>, <https://onco.cc/companies/oncolytics-biotech/>, <https://onco.cc/companies/shanghai-kechow-pharma/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/stcube/>, <https://onco.cc/companies/tiumbio/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/servier/>, <https://onco.cc/companies/gsk/>, <https://onco.cc/companies/guardant-health/>, <https://onco.cc/companies/natera/>, <https://onco.cc/companies/exact-sciences/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/alliance-oncology/> ;
  onco:institutions <https://onco.cc/institutions/nki/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/ncc-japan/>, <https://onco.cc/institutions/johns-hopkins/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/colorectal-cancer-signalling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/cms-subtypes/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/fit-test/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/nordicc/>, <https://onco.cc/trials/symbiotic-gi-03/>, <https://onco.cc/trials/nct07525206/>, <https://onco.cc/trials/nct06614192/>, <https://onco.cc/trials/nct06997497/>, <https://onco.cc/trials/nct06686576/>, <https://onco.cc/trials/nct05141721/>, <https://onco.cc/trials/nct05945901/>, <https://onco.cc/trials/nct03659448/>, <https://onco.cc/trials/proceade-crc-03/>, <https://onco.cc/trials/nct07284849/>, <https://onco.cc/trials/cao-aro-aio-94/>, <https://onco.cc/trials/rapido/>, <https://onco.cc/trials/nct06199973/>, <https://onco.cc/trials/nct04854668/>, <https://onco.cc/trials/nct07221357/>, <https://onco.cc/trials/nct07775287/>, <https://onco.cc/trials/nct07219238/>, <https://onco.cc/trials/nct07228832/>, <https://onco.cc/trials/nct07412613/>, <https://onco.cc/trials/nct05425940/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/nct04547166/>, <https://onco.cc/trials/nct07462143/>, <https://onco.cc/trials/nct07454720/>, <https://onco.cc/trials/nct07722494/>, <https://onco.cc/trials/nct06497985/>, <https://onco.cc/trials/nct07702032/>, <https://onco.cc/trials/nct07361003/>, <https://onco.cc/trials/nct04793958/>, <https://onco.cc/trials/nct07676162/>, <https://onco.cc/trials/nct05890742/>, <https://onco.cc/trials/nct05709249/>, <https://onco.cc/trials/nct06951503/>, <https://onco.cc/trials/nct06662786/>, <https://onco.cc/trials/nct07669454/>, <https://onco.cc/trials/nct06750094/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/nct07669519/>, <https://onco.cc/trials/nct05855200/>, <https://onco.cc/trials/nct05239741/>, <https://onco.cc/trials/nct06968221/> ;
  onco:people <https://onco.cc/people/chadwick-boseman/>, <https://onco.cc/people/angelita-habr-gama/>, <https://onco.cc/people/michael-bretthauer/>, <https://onco.cc/people/aimery-de-gramont/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-capp2-aspirin-lynch-lancet-2020/>, <https://onco.cc/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/> ;
  onco:journals <https://onco.cc/journals/clinical-colorectal-cancer/>, <https://onco.cc/journals/journal-of-gastrointestinal-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/shr-8068/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/oleclumab/>, <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/yl202/>, <https://onco.cc/drugs/jdq443/>, <https://onco.cc/drugs/ql1706/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/sitneprotafib/>, <https://onco.cc/drugs/grt-c901/>, <https://onco.cc/drugs/grt-r902/>, <https://onco.cc/drugs/hr070803/>, <https://onco.cc/drugs/sgm-101/>, <https://onco.cc/drugs/precemtabart-tocentecan/>, <https://onco.cc/drugs/inca33890/>, <https://onco.cc/drugs/ibi363/>, <https://onco.cc/drugs/vs-7375/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/ak119/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/tqb2922/>, <https://onco.cc/drugs/abt-301/>, <https://onco.cc/drugs/botensilimab/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/hdm2017/>, <https://onco.cc/drugs/jyp0015/>, <https://onco.cc/drugs/eik1005/>, <https://onco.cc/drugs/onvansertib/>, <https://onco.cc/drugs/ct3001/>, <https://onco.cc/drugs/sotevtamab/>, <https://onco.cc/drugs/jmt203/>, <https://onco.cc/drugs/tst003/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/circulate-japan/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-crc/>, <https://onco.cc/ideas/idea-immunotherapy-mss-crc/>, <https://onco.cc/pairings/neoadjuvant-io-dmmr/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/drugs/shield/> ;
  onco:standardOfCare <https://onco.cc/drugs/shield/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/technologies/exercise-oncology/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/drugs/shield/>, <https://onco.cc/terms/fit-test/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/trials/atomic/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/paradigm/>, <https://onco.cc/trials/crystal-fire3/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/pairings/anti-egfr-left-sided/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/trials/breakwater/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/pairings/kras-plus-egfr-crc/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/destiny-crc02/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/sunlight/>, <https://onco.cc/trials/fresco-2/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/robotic-surgery/> .